Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
Số trang: 8
Loại file: pdf
Dung lượng: 407.03 KB
Lượt xem: 6
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2(VEGFR-2). This study was conducted to assess the efficacy and safety of apatinib in patients with non-triple-negative metastatic breast cancer who had received prior chemotherapy for their metastatic disease.
Nội dung trích xuất từ tài liệu:
Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
Nội dung trích xuất từ tài liệu:
Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Metastatic breast cancer Multicenter phase II Tyrosine kinase inhibitor Metastatic disease Non-triple-negative breast cancerTài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 173 0 0 -
6 trang 167 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 144 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 121 0 0 -
12 trang 94 0 0
-
19 trang 75 0 0
-
17 trang 65 0 0
-
9 trang 45 0 0
-
12 trang 39 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 38 0 0